Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2000 Nov;69(5):590–594. doi: 10.1136/jnnp.69.5.590

Systematic review of acute levodopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson's disease

C Clarke 1, P Davies 1
PMCID: PMC1763425  PMID: 11032609

Abstract

OBJECTIVES—To perform a systematic review of studies examining the diagnostic accuracy of acute challenge tests with levodopa and/or apomorphine in parkinsonian syndromes to assess their value in the diagnosis of idiopathic Parkinson's disease.
METHODS—A literature search including Medline and the Cochrane Library was performed for studies published in any language comparing acute levodopa and/or apomorphine response with chronic levodopa therapy in parkinsonian syndromes. Abstracted sensitivity and specificity data were summarised using variance weighting and conditional logistic regression for studies comparing two challenge tests.
RESULTS—Thirteen studies were located: four examining de novo patients and nine examining patients with well established idiopathic Parkinson's disease and non-parkinsonian conditions. Despite the significant heterogeneity in the methodologies employed, the comparable results suggest that this had little effect on the accuracy of the tests. The sensitivity for the diagnosis of established idiopathic Parkinson's disease was: apomorphine 0.86 (95% confidence interval (95% CI) 0.78-0.94), acute levodopa 0.75 (95% CI 0.64-0.85), and chronic levodopa therapy 0.91 (95% CI 0.85-0.99). The specificity for the diagnosis of established idiopathic Parkinson's disease was: apomorphine 0.85 (95% CI 0.74-0.96), acute levodopa 0.87(95% CI 0.77-0.97), and chronic levodopa therapy 0.77 (95% CI 0.61-0.93). The number of patients positive for each test divided by the number with clinically diagnosed de novo disease was: apomorphine 0.63 (95% CI 0.56-0.70), acute levodopa 0.69 (95% CI 0.59-0.80), and chronic levodopa therapy 0.76 (95% CI 0.70-0.82).
CONCLUSIONS—The accuracy of the acute levodopa and apomorphine challenge tests is similar to, but not superior than, that of chronic levodopa therapy in the diagnosis of idiopathic Parkinson's disease. As most patients will be given chronic dopamimetic therapy, these tests add nothing while causing significant adverse events and additional cost.



Full Text

The Full Text of this article is available as a PDF (115.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bonuccelli U., Piccini P., Del Dotto P., Rossi G., Corsini G. U., Muratorio A. Apomorphine test for dopaminergic responsiveness: a dose assessment study. Mov Disord. 1993 Apr;8(2):158–164. doi: 10.1002/mds.870080207. [DOI] [PubMed] [Google Scholar]
  2. Brooks D. J. PET and SPECT studies in Parkinson's disease. Baillieres Clin Neurol. 1997 Apr;6(1):69–87. [PubMed] [Google Scholar]
  3. Clarke C. E., Ray P. S., Speller J. M. Failure of the clonidine growth hormone stimulation test to differentiate multiple system atrophy from early or advanced idiopathic Parkinson's disease. Lancet. 1999 Apr 17;353(9161):1329–1330. [PubMed] [Google Scholar]
  4. D'Costa D. F., Abbott R. J., Pye I. F., Millac P. A. The apomorphine test in parkinsonian syndromes. J Neurol Neurosurg Psychiatry. 1991 Oct;54(10):870–872. doi: 10.1136/jnnp.54.10.870. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. D'Costa D. F., Sheehan L. J., Phillips P. A., Moore-Smith B. The levodopa test in Parkinson's disease. Age Ageing. 1995 May;24(3):210–212. doi: 10.1093/ageing/24.3.210. [DOI] [PubMed] [Google Scholar]
  6. Eardley I., Quinn N. P., Fowler C. J., Kirby R. S., Parkhouse H. F., Marsden C. D., Bannister R. The value of urethral sphincter electromyography in the differential diagnosis of parkinsonism. Br J Urol. 1989 Oct;64(4):360–362. doi: 10.1111/j.1464-410x.1989.tb06043.x. [DOI] [PubMed] [Google Scholar]
  7. Gasser T., Schwarz J., Arnold G., Trenkwalder C., Oertel W. H. Apomorphine test for dopaminergic responsiveness in patients with previously untreated Parkinson's disease. Arch Neurol. 1992 Nov;49(11):1131–1134. doi: 10.1001/archneur.1992.00530350045017. [DOI] [PubMed] [Google Scholar]
  8. Hughes A. J., Daniel S. E., Kilford L., Lees A. J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181–184. doi: 10.1136/jnnp.55.3.181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hughes A. J., Lees A. J., Stern G. M. Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes. Lancet. 1990 Jul 7;336(8706):32–34. doi: 10.1016/0140-6736(90)91531-e. [DOI] [PubMed] [Google Scholar]
  10. Hughes A. J., Lees A. J., Stern G. M. Challenge tests to predict the dopaminergic response in untreated Parkinson's disease. Neurology. 1991 Nov;41(11):1723–1725. doi: 10.1212/wnl.41.11.1723. [DOI] [PubMed] [Google Scholar]
  11. Kimber J. R., Watson L., Mathias C. J. Distinction of idiopathic Parkinson's disease from multiple-system atrophy by stimulation of growth-hormone release with clonidine. Lancet. 1997 Jun 28;349(9069):1877–1881. doi: 10.1016/s0140-6736(96)10168-9. [DOI] [PubMed] [Google Scholar]
  12. Linazasoro G. El test de la apomorfina en los síndromes parkinsonianos: valor diagnóstico. Neurologia. 1993 Nov;8(9):288–290. [PubMed] [Google Scholar]
  13. Miranda M., Saéz D. Prueba de apomorfina: evaluación de la respuesta dopaminérgica en parkinsonismos. Rev Med Chil. 1995 Mar;123(3):326–329. [PubMed] [Google Scholar]
  14. Rascol O., Brooks D. J., Korczyn A. D., De Deyn P. P., Clarke C. E., Lang A. E. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med. 2000 May 18;342(20):1484–1491. doi: 10.1056/NEJM200005183422004. [DOI] [PubMed] [Google Scholar]
  15. Roth J., Růzicka E., Mecír P. Apomorfinový test v diferenciální diagnóze parkinsonismu. První zkusenosti. Cas Lek Cesk. 1994 Nov 7;133(21):665–667. [PubMed] [Google Scholar]
  16. Schelosky L., Hierholzer J., Wissel J., Cordes M., Poewe W. Correlation of clinical response in apomorphine test with D2-receptor status as demonstrated by 123I IBZM-SPECT. Mov Disord. 1993 Oct;8(4):453–458. doi: 10.1002/mds.870080406. [DOI] [PubMed] [Google Scholar]
  17. Schulz J. B., Skalej M., Wedekind D., Luft A. R., Abele M., Voigt K., Dichgans J., Klockgether T. Magnetic resonance imaging-based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy. Ann Neurol. 1999 Jan;45(1):65–74. [PubMed] [Google Scholar]
  18. Schwarz J., Tatsch K., Arnold G., Ott M., Trenkwalder C., Kirsch C. M., Oertel W. H. 123I-iodobenzamide-SPECT in 83 patients with de novo parkinsonism. Neurology. 1993 Dec;43(12 Suppl 6):S17–S20. [PubMed] [Google Scholar]
  19. Zappia M., Montesanti R., Colao R., Branca D., Nicoletti G., Aguglia U., Quattrone A. Short-term levodopa test assessed by movement time accurately predicts dopaminergic responsiveness in Parkinson's disease. Mov Disord. 1997 Jan;12(1):103–106. doi: 10.1002/mds.870120118. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES